NIA Impact Advisors’s Moderna MRNA Stock Holding History

NIA Impact Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.77M	Sell	27,575 -3,101	-10%	-$414K	1.57%	26
2023 Q1	$4.71M	Buy	30,676 +355	+1%	+$58.6K	2.54%	17
2022 Q4	$5.45M	Buy	30,321 +900	+3%	+$147K	3.16%	7
2022 Q3	$3.48M	Sell	29,421 -2,625	-8%	-$398K	2.14%	21
2022 Q2	$4.58M	Sell	32,046 -2,776	-8%	-$397K	2.75%	11
2022 Q1	$6M	Buy	34,822 +7,331	+27%	+$1.23M	2.91%	10
2021 Q4	$4.41M	Buy	27,491 +1,360	+5%	+$398K	2.34%	17
2021 Q3	$10.1M	Sell	26,131 -22,073	-46%	-$8.14M	4.29%	2
2021 Q2	$11.3M	Buy	48,204 +893	+2%	+$160K	5.52%	1
2021 Q1	$6.2M	Buy	47,311 +4,384	+10%	+$635K	3.35%	7
2020 Q4	$4.94M	Buy	+42,927	New	+$4.34M	2.57%	14

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NIA Impact Advisors's MRNA Position: Q2 2023 in Review

NIA Impact Advisors reduced its Moderna (MRNA) stake by 10% in Q2 2023, selling an estimated $414K and leaving 27,575 shares worth $2.77M. The position accounts for 1.57% of the portfolio, ranked #26.

NIA Impact Advisors first reported a position in MRNA in Q4 2020 and has held it in 11 quarters since. The position peaked at $11.3M in Q2 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

NIA Impact Advisors held 27,575 shares of Moderna worth $2.77M as of Q2 2023.
NIA Impact Advisors sold 3,101 Moderna shares in Q2 2023, an estimated $414K.
Moderna made up 1.57% of NIA Impact Advisors's portfolio in Q2 2023, its #26 holding.
NIA Impact Advisors first reported a position in Moderna in Q4 2020 and has held it in 11 quarters since.
NIA Impact Advisors's Moderna position peaked at $11.3M in Q2 2021.
965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on NIA Impact Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.